Genentech and OSI Pharmaceuticals will pay $67 million as part of a federal court settlement over misleading claims about the drug Tarceva which was approved to treat non-small-cell lung cancer and advanced stage pancreatic cancer.
Between January 2006 and December 2011, both companies led doctors to believe that Tarceva would work in a broad patient population when it was intended to be used on a narrower patient population that included patients who had never smoked and people who carried a particular mutation in a protein that is involved in the spread and growth of cancer cells.